Abstract 2445
Background
To evaluate the clinicopathological factors and the oncology outcomes of invasive lobular carcinoma (ILC) patients compared with those of invasive ductal carcinoma (IDC) patients.
Methods
This study was a medical record review based on a prospectively-collected database. We surveyed the clinicopathological characteristics and oncology survival between IDC and ILC following curative surgery at ooo Medical Center between March 2007 and February 2015.
Results
The median follow-up time was 60.5 months (range: 3-121 months). There were 352 breast cancer patients with ILC and 7795 breast cancer patients with IDC. There were 13 breast cancer patients with ILC and 1150 breast cancer patients with IDC in the TNBC patients. The IDC patients had 77.7% of cytokeratin (CK) 5/6 and 86.3% of Epidermal growth factor receptor (EGFR), while ILC patients only had 15.4% of CK5/6 and 23.1% of EGFR. In TNBC, patients with ILC showed a tendency to have a worse prognosis than patients with IDC. However, there was no statistical difference in disease-free survival (DFS, p = 0.122) or overall survival (OS, p = 0.093) between TNBC patients with IDC and with ILC.
Conclusions
Patients with ILC have no different oncologic outcome than patients with IDC. However, patients with ILC in TNBC show a tendency to have a worse prognosis than patients with IDC in TNBC. This result may be related to CK5/6 and EGFR. Further research is needed with larger sample sizes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2037 - Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch Colorectal Cancer Group.
Presenter: Johannes Kwakman
Session: Poster Display session 2
Resources:
Abstract
3053 - JFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies.
Presenter: Keisuke Kazama
Session: Poster Display session 2
Resources:
Abstract
3183 - Bevacizumab plus trifluridine/tipiracil in elderly patients with previously untreated metastatic colorectal cancer (KSCC 1602): A single-arm, Phase 2 study
Presenter: Akitaka Makiyama
Session: Poster Display session 2
Resources:
Abstract
3233 - Biweekly TAS-102 and Bevacizumab as a Third-Line Chemotherapy for metastatic colorectal cancer: A Phase II Multicenter Clinical Trial (TAS-CC4 study)
Presenter: Yoichiro Yoshida
Session: Poster Display session 2
Resources:
Abstract
5907 - Liquid biopsy concordance based on clonality and timing of testing in patients with metastatic colorectal cancer
Presenter: Pashtoon Kasi
Session: Poster Display session 2
Resources:
Abstract
1866 - Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer
Presenter: Emilie Moati
Session: Poster Display session 2
Resources:
Abstract
2312 - High Circulating miR-1247 is a marker for poor prognosis in patients with metastatic colorectal cancer treated with chemotherapy and cetuximab
Presenter: Jakob Schou
Session: Poster Display session 2
Resources:
Abstract
5602 - Clinical relevance of circulating tumor (ct)DNA genotyping for first line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): a prospective multicentric study
Presenter: JOANA Vidal Barrull
Session: Poster Display session 2
Resources:
Abstract
3182 - Clonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer
Presenter: Beili Wang
Session: Poster Display session 2
Resources:
Abstract
5205 - Immune status of patients with different stages of colorectal cancer with and without circulating tumor cells
Presenter: Anastasia Sitkovskaya
Session: Poster Display session 2
Resources:
Abstract